PTC Therapeutics, Inc.

PTC Therapeutics, Inc.

PTCTNYSE / NASDAQHealthcareMid cap

$56.42-$1.91 (-3.3%)

Last close · Data as of Nov 20, 2026

Market cap
$5.9B
P/E
8.6x
EV / EBITDA
7.5x
Revenue
$1.7B
Net margin
39.4%
ROCE
35.5%

-26.2% over the last year

PTC Therapeutics, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-10.3%
3M
-20.0%
6M
-20.6%
1Y
-26.2%
5Y
+41.0%

52-week range

Day change -$1.91 (-3.3%) from $58 to $56 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in PTCT, bought on each weekday since 2021.

News & filings

What PTC Therapeutics filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernShareholders' equity is negative: liabilities exceed assets.

Strengths (1)

  • Operating margin of 49.5% against a peer median of 15.0%.
  • Shareholders' equity is negative, so return on equity and debt to equity are not shown.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally.

Read moreShow less

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Sector
Healthcare
Shares outstanding
81.5M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$5.9B
P/E
8.6x
EV / EBITDA
7.5x
EV / Sales
3.8x
P/S
3.4x
52-week high
$89.55
52-week low
$56.42

Profitability

Operating margin
49.5%
Net margin
39.4%
EBITDA margin
51.3%
ROE
-332.5%
ROCE
35.5%
ROA
23.5%
Asset turnover
0.60

Growth

Revenue
$1.7B
Revenue growth, 1Y
114.5%
Revenue CAGR, 3Y
35.3%
Net profit growth, 1Y
-287.9%
Free cash flow
$411.2M

Solvency

Current ratio
2.35
Debt / Assets
0.93
CFO / Net profit
1.04
Cash / Market cap
33.2%

Where the revenue went

Of every $100 of FY2025 revenue, $39 was left as net income.

PTC Therapeutics, Inc. income statement flow, FY2025
PTC Therapeutics, Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$47.0M
RevenueGross profit$1.7B
Gross profitResearch and development$455.3M
Gross profitSelling, general and administrative$347.1M
Gross profitOther operating expenses$24.8M
Gross profitOperating income$856.5M
Operating incomePretax income$696.6M
Operating incomeInterest and other expense$159.9M
Pretax incomeTax and other$14.0M
Pretax incomeNet income$682.6M

Revenue and net profit

Revenue grew 114.5% in FY2025; net profit is the dashed line.

PTC Therapeutics, Inc. revenue and net profit by fiscal year
PTC Therapeutics, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$698.8M-$559.0M
FY2023$937.8M-$626.6M
FY2024$806.8M-$363.3M
FY2025$1.7B$682.6M

Cash flows

FY2025: $711.2M from operations, $411.2M free after investment (dashed).

PTC Therapeutics, Inc. operating and free cash flow by fiscal year
PTC Therapeutics, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$356.7M-$509.1M
FY2023-$158.4M-$279.0M
FY2024-$107.7M-$181.9M
FY2025$711.2M$411.2M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$1.7B+114.5%1Y
EBITDA
$887.7M
Net profit
$682.6M
Cash from operations
$711.2M
Free cash flow
$411.2M
Revenue CAGR, 3Y
35.3%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$1.7B$887.7M$682.6M$411.2M-332.5%+114.5%-287.9%

Monthly returns

Month-by-month returns of PTCT across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$2.9B
Liabilities$3.1B
Equity-$205.3M
Paid-in capital$2.7B
Retained earnings-$3.0B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; PTCT highlighted.

P/E against peers

PTCT trades at 8.6x earnings against a peer median of 17.5x (a 51% discount).

Not shown (no positive earnings and no EV / Sales): Glaukos Corporation, Protagonist Therapeutics, Inc., Teleflex Incorporated.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
PTC Therapeutics, Inc.PTCTthis companyP/E ↓ discount$5.9B8.6x—-332.5%7.5x
Alkermes plcALKS$7.2B29.9x4.0x13.3%20.9x
Glaukos CorporationGKOS$7.1B-38.1x10.9x-28.6%-49.0x
Protagonist Therapeutics, Inc.PTGX$6.6B-50.8x10.8x-21.2%-41.4x
TG Therapeutics, Inc.TGTX$6.2B13.9x9.6x69.0%47.5x
Teleflex IncorporatedTFX$5.8B-6.5x1.9x-29.0%27.1x
Apellis Pharmaceuticals, Inc.APLS$5.3B234.6x14.2x6.0%75.2x
Ligand Pharmaceuticals IncorporatedLGND$4.7B38.0x4.6x12.2%25.3x
Indivior Pharmaceuticals, Inc.INDV$4.4B21.1x-44.7x-212.1%15.1x
Peer median—17.5x7.1x-7.6%23.1x

Year-to-date ROI

PTCT since 1 January, against earlier years.

Historical volatility

PTCT's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

PTC Therapeutics, Inc. operating margin by fiscal year
PTC Therapeutics, Inc. operating margin by fiscal year
DateOperating margin
FY2022-63.0%
FY2023-37.3%
FY2024-18.2%
FY202549.5%
LineFY2025
Cost of revenueCost Of Revenue$47.0M
Gross profitGross Profit$1.7B
Operating expensesOperating Expense$827.1M
Research and developmentResearch And Development$455.3M
Selling, general and administrativeSelling General And Administration$347.1M
Depreciation and amortisationDepreciation And Amortization In Income Statement$24.7M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$24.7M
Amortization$24.7M
Amortisation of intangiblesAmortization Of Intangibles Income Statement$24.7M
Total expensesTotal Expenses$874.1M
Pretax incomePretax Income$696.6M

Learn while you research

Academy chapters picked for PTC Therapeutics, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Value InvestingA P/E of 8.6 could be a value opportunity, or a value trap. Know the difference.7 min read
  3. 03 Growth Investing115% revenue growth is in the top tier, learn how to value growth.7 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →